It is a generic version of Taro Pharmaceuticals USA Inc.'s Topicort Topical Spray, 0.25 per cent.
Drug major Lupin has received approval from the US health regulator to market Desoximetasone Topical spray, a formulation for treatment of plaque psoriasis, in the American market.
It is a generic version of Taro Pharmaceuticals USA Inc.'s Topicort Topical Spray, 0.25%.
The approval has been granted to the product in the size of 30 ml, 50 ml, and 100 ml.
Lupin in a BSE filing said it has received final approval for the spray, 0.25%, from the United States Food and Drug Administration (USFDA).
As per IQVIA MAT data of January 2018, the product had annual sales of around USD 19.5 million in the US.
Shares of Lupin were trading up 1.12% at Rs.770.75 apiece on BSE.